Brief: Magle Chemoswed Signs License Agreement For Amniotic Stem Cell Technology

Magle Chemoswed Holding AB

02/03/2026 07:35

March 2 (Reuters) - Magle Chemoswed Holding AB MAGLE.ST:

SAID ON SATURDAY ENTERED INTO EXCLUSIVE LICENSE AGREEMENT FOR AMNIOTIC STEM CELL TECHNOLOGY WITH ALVION BIO

MAGLE CHEMOSWED AND MAGLE BIOPHARMA TO RECEIVE ROYALTY EQUAL TO 4% OF ALL REVENUES GENERATED FROM COMMERCIALISATION OF THE LICENSED TECHNOLOGY AND/OR LICENSED IPR

 Source text for Workspace: nMFNc5NG3g
 Further company coverage: MAGLE.ST

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))